Novel Btk Inhibitor Heads to Phase III Trials in Chronic Lymphocytic Leukemia

feeds has 409 videos Subscribe Here

Description: An experimental oral drug given once a day is drawing responses from about 70% of patients with relapsed chronic lymphocytic leukemia. Dr. Susan O'Brien explains why investigators are excited about PCI-32765 in an interview at the annual meeting of the American Society of Hematology
Shared By : feeds
Posted on : 12/15/11
Added : 6 years ago

More From feeds

Nothing found.